Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.49 |
| ▸ | ARF6 | P62330 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.32 |
| ▸ | TPSAB1 | Q15661 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lysine SCHEMBL19614976 | 0.90 | PTGDR2 (0.56) | PTGDR2ARF6PRSS1PRSS2PRSS3 | |
| Lysine SCHEMBL19614974 | 0.90 | PTGDR2 (0.56) | PTGDR2ARF6PRSS1PRSS2PRSS3 | |
| SCHEMBL22648114 | 0.86 | PTGDR2 (0.47) | PTGDR2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL20943426 | 0.85 | PTGDR2 (0.54) | PTGDR2ALDH1A1TDP1L3MBTL1MAPT | |
| SCHEMBL3772684 | 0.84 | PTGDR2 (0.54) | PTGDR2ALDH1A1TDP1L3MBTL1MAPT | |
| SCHEMBL3779879 | 0.83 | PTGDR2 (0.64) | PTGDR2TDP1MAPT | |
| SCHEMBL3782624 | 0.80 | PTGDR2 (0.63) | PTGDR2ALDH1A1MAPT | |
| SCHEMBL3777990 | 0.79 | PTGDR2 (0.56) | PTGDR2ALDH1A1L3MBTL1MAPT | |
| SCHEMBL3770942 | 0.78 | PTGDR2 (0.74) | PTGDR2TDP1 | |
| SCHEMBL3778460 | 0.77 | PTGDR2 (0.66) | PTGDR2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043425-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2024-02-08 | — | — | US | disclosed |
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2023-07-25 | — | — | US | disclosed |
| EP-4196478-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022034529-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2022-02-17 | — | — | WO | disclosed |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-02-17 | — | — | US | disclosed |
| US-10626089-B2 | Quinoline derivative in crystal form | GBOO1, Inc. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10626089-B2 | Quinoline derivative in crystal form | GBOO1, Inc. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20190276405-A1 | CRYSTAL OF QUINOLINE DERIVATIVE | GB005, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20190276405-A1 | CRYSTAL OF QUINOLINE DERIVATIVE | GB005, INC. | 2019-09-12 | — | — | US | disclosed |
| EP-3476835-A1 | CRYSTAL OF QUINOLINE DERIVATIVE | Pulmagen Therapeutics (Asthma) Limited (GB) | 2019-05-01 | — | — | EP | disclosed |
| EP-3476835-A1 | CRYSTAL OF QUINOLINE DERIVATIVE | Pulmagen Therapeutics (Asthma) Limited (GB) | 2019-05-01 | — | — | EP | disclosed |
| WO-2017199903-A1 | CRYSTAL OF QUINOLINE DERIVATIVE | 帝人ファーマ株式会社 | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708366-B2 | Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof | REN, NR3C2, PKD1 | PTGDR2 567/4885ARF6 1396/4885PRSS1 377/4885 |
| US-20240043425-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | PTGDR2 567/4885ARF6 1396/4885PRSS1 377/4885 |
| US-20220048909-A1 | HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF | REN, NR3C2, PKD1 | PTGDR2 567/4885ARF6 1396/4885PRSS1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.